Larimar Therapeutics Q3 2024 Earnings Report $1.98 -0.22 (-10.00%) As of 04/3/2025 04:00 PM Eastern Earnings HistoryForecast Larimar Therapeutics EPS ResultsActual EPS-$0.24Consensus EPS -$0.37Beat/MissBeat by +$0.13One Year Ago EPS-$0.21Larimar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALarimar Therapeutics Announcement DetailsQuarterQ3 2024Date10/30/2024TimeAfter Market ClosesConference Call ResourcesLRMR Earnings History Remove Ads Larimar Therapeutics Earnings HeadlinesFY2025 EPS Estimate for Larimar Therapeutics Cut by AnalystMarch 29, 2025 | americanbankingnews.comWilliam Blair Has Negative Outlook for LRMR Q1 EarningsMarch 29, 2025 | americanbankingnews.comBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.April 4, 2025 | Stansberry Research (Ad)Q1 EPS Estimates for Larimar Therapeutics Reduced by WedbushMarch 28, 2025 | americanbankingnews.comLarimar Therapeutics Advances Nomlabofusp Program Amid Regulatory SupportMarch 27, 2025 | msn.comLarimar Therapeutics (NASDAQ:LRMR) Earns "Buy" Rating from GuggenheimMarch 27, 2025 | americanbankingnews.comSee More Larimar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Larimar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Larimar Therapeutics and other key companies, straight to your email. Email Address About Larimar TherapeuticsLarimar Therapeutics (NASDAQ:LRMR), a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.View Larimar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
